Severe Persistent Asthma Care App Asthma is a chronic inflammatory disease of the airways. In the United States, asthma affects more than 22 million persons. It is one of the most common chronic diseases of childhood, affecting more than 6 million children.
This app gives patients who are have severe persistent asthma:
Impairment and risk patient reported outcome surveys
Apple Care Card to track inhaled glucocorticoid use
Patient education content library
Notifications to answer clinically important questions
Integrations with gold standard activity tracker (ie Apple Healthkit)
This App applies Evidence Based Medicine to improve patient care through digital technology . It also gives patients easy access to information from reputable sources including the NIH, Asthma and Allergy Foundation of America, American Lung Association, and American Academy of Allergy, Asthma & Immunology .
National Asthma Education and Prevention Program: Expert panel report III: Guidelines for the diagnosis and management of asthma
Double-blind study, 429 patients who were symptomatic on low-dose inhaled beclomethasone (200 mcg bid) were randomly assigned to receive either increased beclomethasone (500 mcg bid) or the combination of salmeterol (50 mcg bid) plus beclomethasone (200 mcg bid). Both treatments resulted in improvement over baseline, the addition of salmeterol yielded a greater decrease in symptoms and beta-agonist use, improvement in morning peak flow, and reduction in peak flow variability.
The National Asthma Education and Prevention Program (NAEPP) guidelines also suggest a trial of an antileukotriene agent in patients with severe asthma who are not controlled on high dose inhaled GC and LABA. This is reflected in this app.